New studies show the limitations of relying on AI tools for health answers. Platforms must tighten safeguards and educate users on smart prompting.
It’s unlikely to pull users from ChatGPT, but it could increase pressure on tech giants to safeguard user data and avoid overhyping their AI’s medical advice capabilities.
Chatbots and creators become go-to mental health supports for Gen Z as barriers to traditional care persist.
On today’s podcast episode, we discuss the biggest takeaways from the social media addiction trials so far, what our numbers tell us about social media usage in the US, and where else Americans spend their time consuming media. Join Senior Director of Podcasts and host Marcus Johnson, along with Principal Forecasting Writer Ethan Cramer-Flood and Senior Director of Forecasting Oscar Orozco. Listen everywhere, and watch on YouTube and Spotify.
The retailer is sidestepping in-person medical care and insurance complexities in hopes of turning pharmacy traffic into weight loss drug customers.
Brands selling health supplements need transparency around their claims, or doctors won’t recommend them to patients.
Most Americans are wary of AI, but regular users show far higher trust, proving comfort grows with experience.
Data shows the first decline in obesity rates in US adults, but children and teens moved in the opposite direction.
Videos backed by thin evidence rack up views on YouTube, raising stakes for stricter creator guidelines.
New AI capabilities add clinician-vetted, empathetic guidance for women—the predominant segment of its user base.
Drugmakers’ price drops don’t affect all patients the same. Brands and marketers must decode cost complexities where patients already seek out weight loss advice, like on social media.
Two-thirds of clinicians stop engaging with content after clunky interactions.
The offering lets employers subsidize employees’ cash-pay price—sidestepping opaque PBM rebates and helping rein in rising pharmacy costs.
Rising legal and regulatory scrutiny of compounded weight loss drugs suggests branded pharma ties are the safer avenue for telehealth players to sell their copycat GLP-1s.
Its pharma ad lawsuit against J&J’s promotions lands amid rising enforcement and shrinking tolerance for bold claims.
Novo’s drug candidate CagriSema lagged Lilly’s Zepbound in weight loss trials, sending Novo shares down 15% and widening Lilly’s market lead.
Quicker, reliable AI notes help clinicians reclaim minutes they can spend on patients, even as AI accuracy concerns persist.
Tragic news moves consumers’ health choices, signaling to healthcare marketers that they need to pay attention to key cultural moments, not just paid celebrity endorsements.
Justices curb Trump’s tariffs, but a national security case could sustain pharma import taxes.
Single-study clinical trials (versus two) become the default, speeding up common drug approvals, while vaccines still face tougher scrutiny.